Title: Mitochondrial Augmentation Technology: updates on Pearson Syndrome and MDS programs

Company name: Minovia Therapeutics

Website: www.minoviatx.com

CEO name: Natalie Yivgi Ohana

CATEGORY: Biotech

- Aging Redefined: Breakthroughs in Science and Technology in Longevity
- Personalized Pathways; Genetic and cellular based Advances for Rare and Complex Disease

Minovia Therapeutics is a clinical-stage company dedicated to developing therapies suffering mitochondrial disease. From rare diseases to aging, a multi billion $ market opportunity for Mitochondrial Augmentation Technology (MAT). MAT was successfully tested in clinical trials involving pediatric patients with genetic mitochondrial diseases, as well as age-related myelodysplastic syndrome, demonstrating both safety and efficacy.
The company raised $50M to date, including a strategic partnership with Astellas Pharma. A strong management team and board of world experts in the science and business of biotech committed to shape the field of mitochondrial therapies.

Minovia has pioneered a proprietary approach to transplant cells with healthy and functional mitochondria, addressing the root cause of debilitating diseases and aiming to enhance healthy lifespan. MAT employs high-quality mitochondria as therapeutic products.
Our lead product, MNV-201, utilizes the patient's own stem cells, augmented with healthy mitochondria. It is currently being tested in clinical trials for Pearson Syndrome and Low-Risk Myelodysplastic Syndrome (MDS). Preliminary results indicate significant improvements in various disease aspects for Pearson patients—including growth, neurological, muscular, and renal functions, along with notable enhancements in anemia management in MDS patients.

These indications serve as proof-of-concept for MAT, showcasing its potential to enhance cellular activity and combat diseases of the young and old. Minovia's long-term vision is to advance this technology into the healthy longevity sector, paving the way for future studies focused on aging.

MNV-201 is currently in Phase II for Pearson Syndrome, being a rare pediatric disease, a single pivotal trial is currently being designed, expected to execute in the coming year. BLA around H1 2028; PRV expected to yield ~$100M in revenue. MNV-201 is in Phase I for low risk MDS under IND. 4 out of 9 patients

were treated. Next steps will be to finish the Israeli trial, open US sites and start multi-center phase II in US and IL. Our goal is to identify strategic partner for the further development and commercialization of MDS.

Minovia is currently raising Round A aiming to expand to US, open manufacturing, clinical sites and operations.